Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women

Climacteric

Volumn 16, Issue 2, 2013, Pages 252-257

  Yu, H ^a   Racketa, J ^a   Chines, A A ^a   Mirkin, S ^a  

^a PFIZER INC   (United States)

Author keywords

Bazedoxifene Conjugated Estrogens; Hot Flushes; Selective Estrogen Receptor Modulators; Symptom Free Days; Tissue Selective Estrogen Complex; Vasomotor

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOT FLUSH; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT DURATION;

ADULT; AGED; DOUBLE-BLIND METHOD; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 84875184479     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.717996     Document Type: Article

References (27)

1. Fugate Woods N, Sullivan Mitchell E. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118: 14-24S
2. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006; 96: 1226-35
3. Riggs BL, Khosla S, Melton LJ III. A unitary model for invo-lutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13: 763-73
4. National Osteoporosis Foundation. Fast facts on osteoporosis. http://www.nof.org/node/40 [serial online]; Accessed November 17, 2011
5. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 4: CD002978
6. North American Menopause Society. Estrogen and progesto-gen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-55
7. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-7
8. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without proges-tins. J Natl Cancer Inst 1999; 91: 1131-7
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
10. Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause 2005; 12: 399-404
11. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008; 149: 6084-91
12. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008; 15: 984-92
13. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/con-jugated estrogens for osteoporosis prevention in at-risk postmen-opausal women. Fertil Steril 2009; 92: 1045-52
14. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of baze-doxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92: 1025-38
15. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009; 92: 1039-44
16. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92: 1018-24
17. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116-24
18. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo-And active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010; 17: 281-9
19. Lobo RA, Belisle S, Creasman WT, et al. Should symptomatic menopausal women be offered hormone therapy? MedGenMed 2006; 8: 40
20. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Baze-doxifene/conjugated estrogens and quality of life in postmeno-pausal women. Maturitas 2009; 63: 329-35
21. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women. Menopause 2010; 17: 1237-8
22. Prior JC, Nielsen JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond) 2007; 112: 517-25
23. Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med 1999; 44: 286-96
24. Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010; 118: 117-24
25. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009; 150: 1897-903
26. Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 2009; 23: 75-85
27. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010; 13: 132-40